CryoLife, Inc. (NYSE:CRY) Director C Elkins Ronald sold 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $22.00, for a total transaction of $22,000.00. Following the completion of the transaction, the director now directly owns 101,849 shares of the company’s stock, valued at approximately $2,240,678. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

CryoLife, Inc. (CRY) traded up 0.46% during trading on Wednesday, reaching $21.95. 204,668 shares of the company’s stock traded hands. The company has a 50 day moving average price of $19.24 and a 200-day moving average price of $18.08. The company has a market cap of $734.14 million, a PE ratio of 66.52 and a beta of 0.97. CryoLife, Inc. has a 12-month low of $14.02 and a 12-month high of $22.85.

CryoLife (NYSE:CRY) last announced its quarterly earnings data on Monday, July 24th. The medical equipment provider reported $0.12 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.10 by $0.02. CryoLife had a net margin of 6.16% and a return on equity of 7.41%. The business had revenue of $47.80 million for the quarter, compared to analyst estimates of $47.02 million. During the same period last year, the business earned $0.13 EPS. The company’s revenue was up 1.5% on a year-over-year basis. On average, equities research analysts forecast that CryoLife, Inc. will post $0.43 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “C Elkins Ronald Sells 1,000 Shares of CryoLife, Inc. (CRY) Stock” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/06/c-elkins-ronald-sells-1000-shares-of-cryolife-inc-cry-stock.html.

Institutional investors and hedge funds have recently made changes to their positions in the company. State of Alaska Department of Revenue raised its holdings in shares of CryoLife by 80.8% in the 2nd quarter. State of Alaska Department of Revenue now owns 5,387 shares of the medical equipment provider’s stock valued at $107,000 after purchasing an additional 2,407 shares in the last quarter. First Mercantile Trust Co. raised its holdings in shares of CryoLife by 5.6% in the 2nd quarter. First Mercantile Trust Co. now owns 5,448 shares of the medical equipment provider’s stock valued at $109,000 after purchasing an additional 291 shares in the last quarter. Municipal Employees Retirement System of Michigan raised its holdings in shares of CryoLife by 3.2% in the 1st quarter. Municipal Employees Retirement System of Michigan now owns 6,150 shares of the medical equipment provider’s stock valued at $102,000 after purchasing an additional 190 shares in the last quarter. Mason Street Advisors LLC raised its holdings in shares of CryoLife by 7.4% in the 1st quarter. Mason Street Advisors LLC now owns 6,324 shares of the medical equipment provider’s stock valued at $105,000 after purchasing an additional 438 shares in the last quarter. Finally, Creative Planning raised its holdings in shares of CryoLife by 3.0% in the 2nd quarter. Creative Planning now owns 6,806 shares of the medical equipment provider’s stock valued at $136,000 after purchasing an additional 200 shares in the last quarter. Institutional investors and hedge funds own 68.85% of the company’s stock.

CRY has been the topic of several analyst reports. Zacks Investment Research raised shares of CryoLife from a “hold” rating to a “buy” rating and set a $21.00 price target on the stock in a report on Thursday, June 8th. BidaskClub lowered shares of CryoLife from a “buy” rating to a “hold” rating in a report on Monday, July 24th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $22.00.

CryoLife Company Profile

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.